Compare · head to head
Coherus Oncology vs Janux Therapeutics
Coherus Oncology ranks higher overall — 360 rank 72 vs 41.
Coherus Oncology leads on Quality (53 vs 47), Growth (60 vs 52) and Safety (61 vs 30). Janux Therapeutics leads on Sentiment (66 vs 49).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Small | Small |
| ISIN | US19249H1032 | US47103J1051 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 72 | 41 |
| Value | NR | 46 |
| Quality | 53 | 47 |
| Growth | 60 | 52 |
| Safety | 61 | 30 |
| Sentiment | 49 | 66 |
| Quality details | ||
| Profitability | 55 | 58 |
| Cash Truth | NR | 36 |
Coherus Oncology vs IncyteCoherus Oncology vs ExelixisCoherus Oncology vs MeiraGTxCoherus Oncology vs Bicara TherapeuticsAdd a third stock →
Full analyses: Coherus Oncology · Janux Therapeutics
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100